{"name":"AlphaVax, Inc.","slug":"alphavax-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AVX502","genericName":"AVX502","slug":"avx502","indication":"Other","status":"phase_1"},{"name":"AVX101","genericName":"AVX101","slug":"avx101","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AVX502","genericName":"AVX502","slug":"avx502","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVX101","genericName":"AVX101","slug":"avx101","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQeGd6SlZ2M3ZTTHpjOU5wLU9MMXFVQmE2SVVtX29iOFRlTkdjNTlablA0WVBwWFloU0dpRkFUcmVtXzhfS1hybUVtdWR3MXliUFF5b2RlN2xlbE54ZTI5bW5waWNVVGtqZlFyVER4V05ubGdwQUhXblJrNFpCTzVhMzExRjVRcS1wY2lGTEh5MVlpTFdsczZlVDhkUGxVUlFKandwY0JUbnlDRG5uS3p6b01lZm5oS3ZDYmxCSllhVGxpeUxrN2J4Z25GRzRteG1HdTNtSGpGNGhPSlUtc2RUQ3VBekNHT08zeXhxaGU1d3E2QnJDWEFsck9fcTlta1JuaHlodVVkb2s?oc=5","date":"2018-10-05","type":"pipeline","source":"openPR.com","summary":"BOTULISM ILLNESS MARKET 2023 REPORT OVERVIEW BY TOP KEY PLAYERS - openPR.com","headline":"BOTULISM ILLNESS MARKET 2023 REPORT OVERVIEW BY TOP KEY PLAYERS","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}